BPC-157 + TB-500

This research blend combines BPC-157 (5 mg) and TB-500 (5 mg) in a single lyophilized vial for studies investigating synergistic tissue repair mechanisms. The rationale for this combination is based on their complementary mechanisms: BPC-157 promotes angiogenesis via VEGFR2 upregulation, modulates the nitric oxide system, protects gastrointestinal mucosa, and influences growth factor expression (EGF, FGF, TGF-β), while TB-500 upregulates actin polymerization, promotes endothelial and keratinocyte cell migration, reduces inflammation through cytokine modulation, and supports extracellular matrix remodeling. Together, they address tissue repair from both the vascular supply side (BPC-157's angiogenic effects) and the cellular migration/proliferation side (TB-500's actin-mediated motility enhancement). Preclinical research suggests this combination may produce tissue repair outcomes greater than either compound alone, with potential applications in musculoskeletal injury models, gastrointestinal healing studies, and post-surgical recovery research.